Skip to main content
. Author manuscript; available in PMC: 2013 Aug 1.
Published in final edited form as: J Stroke Cerebrovasc Dis. 2011 Jan 14;21(6):436–444. doi: 10.1016/j.jstrokecerebrovasdis.2010.11.002

Table 4.

Results of longitudinal models of cognitive function among participants free of MCI at baseline.

3MSE ADAS-cog
Exposure Slope1 (95% CI) p-
value2 		Slope 1 (95% CI) p-
value2
No LLM

Statin ever

Other LLM ever		 −0.11 (−0.15, −
0.07)

−0.06 (−.10, −.01)

−0.16 (−0.29, −
0.04)

.066

.43		 0.05 (0.02,
0.07)

0.015 (−0.01,
0.04)

−0.03 (−0.11, −
0.04)

.058

.041
Statin use

    None

    Former

    Current

−0.14 (−0.18, −
0.10)

− 0.06 (−0.18,
0.07)

−0.07 (−0.12, −
0.02)



.19

.014

0.04 (0.02, 0.07)

0.03(−0.05, 0.11)

0.01 (−0.02, 0.04)



.73

.045
Type of statin (ever
use)

    None

    Lipophilic

    Nonlipophilic

−0.10 (−0.14, −
0.06)

−0.06 (−0.11, −
0.01)

−0.16 (−0.26, −
0.06)



.13

.26

0.04 (0.02, 0.06)

0.01 (−0.02, 0.03)

0.05 (−0.00, 0.11)



.044

.66
1

Estimate of rate of change at midpoint of follow-up time.

2

Test for difference in slope compared to non-users.